| Literature DB >> 22222676 |
P Monica Lind1, Bert van Bavel, Samira Salihovic, Lars Lind.
Abstract
BACKGROUND ANDEntities:
Mesh:
Substances:
Year: 2012 PMID: 22222676 PMCID: PMC3261941 DOI: 10.1289/ehp.1103563
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Figure 1An ultrasonographic image of the left carotid artery from a study participant. The blood inside the artery appears black. The right side of the image shows the part of the common carotid artery where IMT and IM-GSM are measured (rectangle). IMT is the thickness of that part of the vascular wall, and IM-GSM is a measure of the echogenicity (gray scale) of the same part of the wall. At the left side of the image, the carotid artery has divided into an internal part and an external part. In the bifurcation region, two plaques are outlined.
Selected basic characteristics and major CV risk factors in the PIVUS study (n = 1,016; 50.2% females).
| Variable | Mean ± SD or | Median (range) | ||
|---|---|---|---|---|
| Height (cm) | 169 ± 9.1 | 169 (151–190) | ||
| Weight (kg) | 77 ± 14 | 76 (49–116) | ||
| Waist circumference (cm) | 91 ± 12 | 90 (67–123) | ||
| BMI (kg/m2) | 27.0 ± 4.3 | 26.6 (19.1–39) | ||
| Waist:hip ratio | 0.90 ± 0.075 | 0.90 (0.73–1.08) | ||
| SBP (mmHg) | 150 ± 23 | 148 (105–210) | ||
| DBP (mmHg) | 79 ± 10 | 78 (56–105) | ||
| Serum cholesterol (mmol/L) | 5.4 ± 1.0 | 5.4 (3.2–7.8) | ||
| LDL cholesterol (mmol/L) | 3.3 ± 0.88 | 3.3 (1.4–5.6) | ||
| HDL cholesterol (mmol/L) | 1.5 ± 0.42 | 1.4 (0.8–2.9) | ||
| Serum triglycerides (mmol/L) | 1.3 ± 0.60 | 1.15 (0.46–3.6) | ||
| Fasting blood glucose (mmol/L) | 5.3 ± 1.6 | 5 (3.8–13.5) | ||
| IMT | 0.88 ± 0.16 | 0.87 (0.58–1.35) | ||
| IM-GSM | 78.8 ± 23.8 | 75.5 (37–143.5) | ||
| Current smoking | 107 (11) | — | ||
| History of myocardial infarction | 72 (7) | — | ||
| History of stroke | 37 (4) | — | ||
| History of diabetes mellitus | 88 (9) | — | ||
| Any CV medication | 461 (45) | — | ||
| Antihypertensive medication | 317 (31) | — | ||
| Statin treatment | 149 (15) | — | ||
| Insulin therapy | 18 (2) | — | ||
| Oral antiglycemic drug therapy | 62 (6) | — | ||
| No carotid artery plaque | 327 (35) | — | ||
| Unilateral carotid plaque | 343 (36) | — | ||
| Bilateral carotid plaque | 273 (29) | — |
Serum concentrations (pg/mL) of POPs in the PIVUS study (n = 1,016; 50.2% females).
| POP | Detection rate (%) | LOD | POP concentration [median (25th–75th percentile)] | |||
|---|---|---|---|---|---|---|
| PCBs | ||||||
| PCB-74 (2,2´,4,4´,5-pentachlorobiphenyl) | 100 | 8.5 | 91.4 (63.9–128.1) | |||
| PCB-99 (2,2´,4,4´,5-pentachlorobiphenyl) | 99.5 | 10.0 | 90.9 (62.4–131.9) | |||
| PCB-105 (2,3,3´,4,4´-pentachlorobiphenyl) | 100 | 5.9 | 32.0 (21.0–46.8) | |||
| PCB-118 (2,3´,4,4´,5-pentachlorobiphenyl) | 100 | 25.3 | 200.6 (136.4–281.0) | |||
| PCB-126 (3,3´,4,4´,5-pentachlorobiphenyl) | 95.6 | 8.0 | 40.4 (71.9–385.8) | |||
| PCB-138 (2,2´,3,4,4´,5´-hexachlorobiphenyl) | 99.6 | 108.7 | 819.3 (619.2–1115.8) | |||
| PCB-153 (2,2´,4,4´,5,5´-hexachlorobiphenyl) | 100 | 117.7 | 1427.6 (1114.4–1847.9) | |||
| PCB-156 (2,3,3´,4,4´,5-hexachlorobiphenyl) | 100 | 10.8 | 154.3 (118.7–197.6) | |||
| PCB-157 (2,3,3´,4,4´,5´-hexachlorobiphenyl) | 100 | 1.5 | 28.0 (21.4–37.0) | |||
| PCB-169 (3,3´,4,4´,5,5´-hexachlorobiphenyl) | 99.7 | 17.5 | 171.4 (130.1.9–636.4) | |||
| PCB-170 (2,2´,3,4,4´,5,5´-heptachlorobiphenyl) | 100 | 38.9 | 497.5 (385.7–633) | |||
| PCB-180 (3,3´,4,4´,5,5´-hexachlorobiphenyl) | 100 | 65.3 | 1165.4 (917.8–1487.8) | |||
| PCB-189 (2,3,3´,4,4´,5,5´-heptachlorobiphenyl) | 100 | 1.7 | 19.3 (14.6–25.8) | |||
| PCB-194 (2,2´,3,3´,4,4´,5,5´-octachlorobiphenyl) | 98.6 | 4.2 | 119.4 (87.6–158.9) | |||
| PCB-206 (2,2´,3,3´,4,4´,5,5´,6-nonachlorobiphenyl) | 100 | 0.8 | 26.8 (20.8–35.2) | |||
| PCB-209 (2,2´,3,3´,4,4´,5,5´,6,6´-decachlorobiphenyl) | 100 | 1.2 | 26.2 (19.6–34.7) | |||
| OCDD | 80.6 | 1.4 | 2.6 (1.4–4.2) | |||
| OC pesticides | ||||||
| HCB | 98.6 | 89.1 | 253.6 (189.1–336.5) | |||
| 9.6 | — | < LOD | ||||
| 3.4 | — | < LOD | ||||
| 100 | 5.9 | 139.6 (91.6–211.4) | ||||
| DDE | 100 | 11.5 | 1859.8 (1024.0–3472.1) | |||
| BDE-47 (2,2´,4,4´-tetra-bromodiphenyl ether) | 77.2 | 9.2 | 12.6 (9.0–19.5) | |||
Relationships among POPs, plaques in the carotid artery, and echogenicity IM-GSM in the common carotid artery (ln-transformed continuous variables).
| Carotid plaques | IM-GSM | IMT | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| POP | OR (95% CI) | Multiple adjusted | Regression coefficient (95% CI) | Multiple adjusted | Regression coefficient (95% CI) | Multiple adjusted | ||||||
| PCB-74 | 1.28 (1.00, 1.63) | 0.054 | 2.3 (–0.71, 5.29) | 0.14 | 0.15 (–0.005, 0.035) | 0.17 | ||||||
| PCB-99 | 1.29 (1.04, 1.61) | 0.02 | 0.41 (–2.19, 3.01) | 0.76 | 0.001 (–0.016, 0.019) | 0.87 | ||||||
| PCB-105 | 1.07 (0.86, 1.33) | 0.53 | 0.77 (–1.88, 3.43) | 0.57 | 0.0016 (–0.016, 0.019) | 0.86 | ||||||
| PCB-118 | 1.16 (0.88, 1.44) | 0.31 | 0.69 (–2.25, 3.63) | 0.65 | 0.002 (–0.018, 0.022) | 0.84 | ||||||
| PCB-126 | 1.06 (0.93, 1.21) | 0.44 | –3.26 (–4.92, –1.61) | 0.0001 | 0.013 (0.002, 0.024) | 0.022 | ||||||
| PCB-138 | 1.46 (1.11, 1.93) | 0.007 | –1.24 (–4.54, 2.05) | 0.46 | 0.008 (–0.014, 0.030) | 0.46 | ||||||
| PCB-153 | 1.65 (1.22, 2.25) | 0.001 | –0.10 (–3.72, 3.53) | 0.96 | 0.011 (0.013, 0.035) | 0.38 | ||||||
| PCB-156 | 1.95 (1.41, 2.71) | 0.0001 | 1.41 (–2.41, 5.23) | 0.47 | 0.001 (–0.025, 0.026) | 0.95 | ||||||
| PCB-157 | 1.56 (1.17, 2.06) | 0.002 | –1.41 (–4.80, 1.97) | 0.42 | 0.034 (0.011, 0.057) | 0.003 | ||||||
| PCB-169 | 1.18 (0.87, 1.59) | 0.28 | –1.66 (–5.07, 1.75) | 0.34 | 0.002 (–0.022, 0.026) | 0.86 | ||||||
| PCB-170 | 2.02 (1.43, 2.85) | 0.0001 | –1.93 (–6.04, 2.18) | 0.36 | 0.022 (–0.006, 0.050) | 0.13 | ||||||
| PCB-180 | 1.86 (1.33, 2.61) | 0.0001 | –3.17 (–7.21, 0.87) | 0.12 | 0.024 (–0.004, 0.051) | 0.09 | ||||||
| PCB-189 | 1.15 (0.95, 1.39) | 0.15 | –0.75 (–3.11, 1.60) | 0.53 | 0.007 (–0.009, 0.023) | 0.41 | ||||||
| PCB-194 | 1.14 (0.97, 1.33) | 0.102 | –10.30 (–12.13, –8.47) | 0.0001 | 0.016 (0.002, 0.029) | 0.020 | ||||||
| PCB-206 | 1.66 (1.24, 2.23) | 0.001 | –9.64 (–13.09, –6.18) | 0.0001 | 0.031 (0.007, 0.055) | 0.012 | ||||||
| PCB-209 | 1.51 (1.16, 1.95) | 0.002 | –13.24 (–16.30, –10.77) | 0.0001 | 0.026 (0.004, 0.048) | 0.018 | ||||||
| OCDD | 1.31 (1.06, 1.62) | 0.01 | 2.97 (0.39, 5.55) | 0.024 | –0.017 (–0.019, 0.016) | 0.85 | ||||||
| HCB | 1.20 (0.90, 1.60) | 0.21 | 9.01 (5.49, 12.52) | 0.0001 | –0.001 (–0.024, 0.024) | 0.99 | ||||||
| TNC | 1.33 (1.07, 1.66) | 0.010 | 6.29 (3.67, 8.91) | 0.0001 | –0.002 (–0.020, 0.016) | 0.82 | ||||||
| DDE | 1.02 (0.89, 1.17) | 0.80 | –2.53 (–4.21, –0.86) | 0.003 | –0.004 (–0.015, 0.007) | 0.49 | ||||||
| BDE-47 | 1.12 (0.93, 1.34) | 0.24 | 2.42 (0.17, 4.67) | 0.035 | –0.008 (–0023, 0.0073) | 0.31 | ||||||
| Sum of PCBs (concentration) | 1.03 (1.01, 1.05) | 0.002 | –0.40 (–0.65, –0.14) | 0.002 | 0.001 (–0.00004, 0.0033) | 0.057 | ||||||
| Total TEQ | 1.09 (0.90, 1.33) | 0.34 | –4.83 (–7.15, –2.52) | 0.0001 | 0.021 (0.0052, 0.037) | 0.009 | ||||||
| TEQ for dioxin-like mono- | 1.67 (1.20, 2.32) | 0.002 | 1.06 (–2.88, 5.02) | 0.60 | 0.010 (–0.016, 0.037) | 0.44 | ||||||
| TEQ for dioxin-like coplanar, non‑ | 1.09 (0.90, 1.32) | 0.36 | –4.50 (–6.79, –2.21) | 0.0001 | 0.020 (0.0045, 0.037) | 0.012 | ||||||
| Penta-PCBs (concentration) | 1.04 (0.98, 1.11) | 0.12 | –0.52 (–1.26, 0.21) | 0.16 | 0.0029 (–0.0020, 0.0079) | 0.25 | ||||||
| Hexa-PCBs (concentration) | 1.12 (1.05, 1.21) | 0.001 | –0.22 (–1.04, 0.60) | 0.60 | 0.0034 (–0.0021, 0.0089) | 0.23 | ||||||
| Hepta-PCBs (concentration) | 1.17 (1.06, 1.30) | 0.0001 | –0.68 (–1.91, 0.55) | 0.28 | 0.0059 (–0.0024, 0.014) | 0.16 | ||||||
| Octa- to deca-PCBs (concentrations) | 1.11 (1.03, 1.20) | 0.007 | –4.71 (–5.65, –3.77) | 0.0001 | 0.0090 (0.0022, 0.015) | 0.009 | ||||||